Latest in News & Research
Biologics Are Safe for Patients With Psoriasis, Cancer
Biologics do not affect cancer progression, while predictors of progression include advanced cancer stage, higher comorbidity burden
Survival Similar for Men, Women With Metastatic Melanoma Receiving Immunotherapy
Women had improved survival without immunotherapy, but similar survival with immunotherapy
Weight-Loss Interventions Seem Beneficial in Psoriasis
Review of randomized controlled trials shows interventions improve psoriasis severity and quality of life
Nemolizumab Rapidly Relieves Itch, Sleep Disturbance in Atopic Dermatitis
Data from four randomized clinical trials confirm benefits by day 2 in atopic dermatitis, prurigo nodularis
5-Fluorouracil Successful for Bowen Disease in Long Term
Negligible additional risk for recurrence seen after 5FU or surgical excision; negligible risk for cutaneous squamous cell carcinoma reported from treated BD
Iron Deficiency Without Anemia Common With Moderate-to-Severe Atopic Dermatitis
Furthermore, iron deficiency is associated with higher clinical burden
Vixarelimab Demonstrates Sustained Dose-Dependent Benefits for Prurigo Nodularis
Significant reduction seen in the mean Worst Itch Numeric Rating Scale scores for high-, mid-, low-dose vixarelimab versus placebo
New Sunscreen Ingredient Could Soon Be Allowed in the U.S.
The U.S. Food and Drug Administration is reviewing bemotrizinol, a sunscreen ingredient used widely overseas
Study Explores the Etiology of Melanoma Associated With Tanning Bed Usage
Tanning bed users more likely to have melanoma on body sites with low cumulative levels of sun damage, to have multiple melanomas
Flipped Dose Nivolumab + Ipilimumab Beneficial in Advanced Unresectable Melanoma
Adjusted hazard ratio for progression-free and overall survival significantly lower for NIVO3+IPI1 versus NIVO1+IPI3
Causal Effect Suggested for BMI, IBD on Hidradenitis Suppurativa
Mendelian randomization analyses support effect of BMI and IBD, with no signs of pleiotropy
Botulinum Toxin Safe, Effective for Refractory Digital Ischemia
High rates of complete response seen for ischemia, ulcers, gangrene; adverse events occurred infrequently
Long-Term Durable Responses to Cemiplimab Seen in Advanced CSCC
Of four patients receiving retreatment with cemiplimab, three remained progression-free at data cutoff
Rocatinlimab Yields Significant Improvements in Atopic Dermatitis
Significant improvements seen in coprimary end points of EASI-75 response and vIGA-AD score of 0 or 1 versus placebo
RSNA: Ultrasound Findings Can ID Cosmetic Filler-Linked Vascular Adverse Events
With ultrasound findings, the exact place where the occlusion occurs can be targeted
CatBoost Model Has Best Performance for Predicting Survival in Melanoma
Model achieved area under the curve values of 0.7577, 0.7595, and 0.7557 for one-, three-, and five-year survival predictions
Dermatoscopes Compared for Dermoscopy Performance, Teledermatology Use
Ambient light and polarized dermatoscopes both enable dermoscopy performance and receipt of teledermatology recommendations
FDA Approves Updated Label for Unloxcyt
Approval is for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation
Slight Increase in Global Burden of Psoriasis Seen Through 2021
Age-standardized incidence rate projected to continue increasing through 2050 in males and females based on data through 2021
Melanoma Incidence Has Decreased Among Young Men in the United States
Decline in melanoma incidence seen among men, but not women younger than 40 years; no difference seen between older men and women
Chronic Pruritus Prevalent Among Older Adults
Atopic dermatitis and psychological symptoms were associated with greatest impairment in pruritus-specific QoL
Introducing Amy Jones and PANP360: A New Era for PAs and NPs in Dermatology
PANP360 brings dermatology PAs and NPs a place to learn, connect, and grow—clinically and as whole people.
Prevalence of Primary Epithelioid Sarcoma Is 0.49 per 100,000 in the U.S.
Prevalence was highest among Whites, lowest among American Indians; highest prevalence seen for those aged 35 to 39 years
24 of 1289